Each new drug evaluation project includes an early biomarker discovery program to improve cancer patient selection and stratification in clinical trials. All cancer features associated with drug sensitivities (including histotype, genomic alterations and gene expression profiles) are systematically revealed by using various statistical tests. In this way, algorithms and  predictive models are developed to determine individual cancer susceptibility to therapies.

​

​

Our platform integrates tools to match and compare patient tumor information to preclinical models. This approach provides precise information on targets in patient tumors to identify those that will most likely respond to a given compound. The approach leaves out cancer patients that would otherwise be inappropriately selected in clinical trials, thereby unnecessary treatment is avoided, thus increasing the chances of clinical trial success.